At a glance
Foresite Capital appears in 2 funding rounds tracked by ValueAddVC since 2026. Its most recent tracked deal was KymaThera's $80M Series B round (Oct 6, 2026).
Strategy
Recent changes
- Oct 6, 2026Oct 6, 2026Invested in KymaThera (Series B, $80M) Pulse2.com
- Aug 13, 2026Aug 13, 2026Invested in Khartis Therapeutics (Series B, $50M) Axios
Portfolio
3 totalRecent Investment Activity
2Track record: led 0 and participated in 2 of 2 tracked venture rounds · 2 in the last 12 months
| Date | Company | Event | Role | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | KymaThera | Series B | Participated | $80M | — | Pulse story | |
| Aug 13, 2026 | Khartis Therapeutics | Series B | Participated | $50M | — | Foresite CapitalunverifiedLilly Asia VenturesunverifiedNextech InvestunverifiedForge Life Science Partners | Pulse story |
Co-Investors
8Similar Firms
overlapping sector, stage or regionLatest Pulse
- Oct 6, 2026KymaThera Raises $80M For A Precision Cancer DrugKymaThera raised an $80 million Series B led by Alta Partners to advance K-1728, an oral PI3K-alpha inhibitor designed to treat breast cancer and vascular malformations while avoiding the toxicity that has limited earlier drugs in its class.→
- Sep 4, 2026Thyme Care Doubles to $2B on Cancer NavigationMorgan Health led a $125 million Series E with Humana and CVS Health Ventures joining, as the Nashville company's oncology navigation service reached 135,000 actively treated patients.→
- Aug 13, 2026Khartis Emerges From Stealth With $95M for a Thyroid PillKhartis Therapeutics emerged from stealth with $95 million in total funding, including a new $50 million Series B, to develop an oral alternative to injectable treatments for thyroid eye disease.→
- Aug 4, 2026Latigo Sets Terms for a $272M Nasdaq IPOLatigo Biotherapeutics set terms for a $272M Nasdaq IPO under ticker LTGO, pricing 16M shares at $16-18 to fund late-stage trials of its non-opioid Nav1.8 pain drug, a rival to Vertex's Journax.→
Foresite Capital FAQ
What companies has Foresite Capital invested in?
Foresite Capital's portfolio includes KymaThera, Khartis Therapeutics, Latigo Biotherapeutics.
Who does Foresite Capital co-invest with most?
In the rounds Value Add tracks, Foresite Capital most often invests alongside 5AM Ventures (1 shared deal), Ascenta Capital (1 shared deal), Blue Owl Capital (1 shared deal), Nextech Invest (1 shared deal), Qatar Investment Authority (1 shared deal).
Sources & methodologyshow
- Axiosmajor outlet1 fact
- Pulse2.comValue Add VC data1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.